Research graph
References from EGFR-Targeted Nanoparticle Delivery of Osimertinib for Triple-Negative and Metastatic Breast Cancer Therapy. Local targets link to admitted publications; unresolved targets remain external evidence.
10.3390/ph14060589
10.3390/ph14060589 · External reference
Triple-negative breast cancer molecular subtyping and treatment progress
10.1186/s13058-020-01296-5 · 2020 · External reference
10.3390/ph15050542
10.3390/ph15050542 · External reference
FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation
10.1634/theoncologist.2017-0425 · 2018 · External reference
10.3390/cancers17040668
10.3390/cancers17040668 · External reference
EGFR Mutations in Surgically Resected Fresh Specimens from 697 Consecutive Chinese Patients with Non-Small Cell Lung Cancer and Their Relationships with Clinical Features
10.3390/ijms141224549 · 2013 · External reference
Targeting EGFR in Lung Cancer: Current Standards and Developments
10.1007/s40265-018-0916-4 · 2018 · External reference
Adjuvant Osimertinib: A New Standard of Care
10.1002/onco.13634 · 2021 · External reference
EGFR targeted therapy in lung cancer; an evolving story
2017 · External reference
Paclitaxel and Lapatinib dual loaded chitosan-coated PLGA nanoparticles enhance cytotoxicity by circumventing MDR1-mediated trastuzumab resistance in HER2 positive breast cancers: In-vitro and in-vivo studies
10.1016/j.jddst.2022.103445 · 2022 · External reference
10.3390/pr10071329
10.3390/pr10071329 · External reference
Novel Silibinin Loaded Chitosan-Coated PLGA/PCL Nanoparticles Based Inhalation Formulations with Improved Cytotoxicity and Bioavailability for Lung Cancer
10.1007/s12668-020-00797-z · 2021 · External reference
A fast, sensitive and greener stability-indicating HPLC method for the quantitative determination of osimertinib
2025 · External reference
An Osimertinib-Perfluorocarbon Nanoemulsion with Excellent Targeted Therapeutic Efficacy in Non-small Cell Lung Cancer: Achieving Intratracheal and Intravenous Administration
10.1021/acsnano.2c04159 · 2022 · External reference
Chitooligosaccharides-modified PLGA nanoparticles enhance the antitumor efficacy of AZD9291 (Osimertinib) by promoting apoptosis
10.1016/j.ijbiomac.2020.06.154 · 2020 · External reference
Pulmonary delivery of osimertinib liposomes for non-small cell lung cancer treatment: Formulation development and in vitro evaluation
10.1007/s13346-021-01088-0 · 2022 · External reference
Chitosan-Coated-PLGA Nanoparticles Enhance the Antitumor and Antimigration Activity of Stattic—A STAT3 Dimerization Blocker
10.2147/ijn.s337093 · 2022 · External reference
10.3390/coatings11010006
10.3390/coatings11010006 · External reference
Single emulsion-solvent evaporation technique and modifications for the preparation of pharmaceutical polymeric nanoparticles
10.2174/187221112802652633 · 2012 · External reference
Chitosan-Coated Poly(lactic-co-glycolic acid) Nanoparticles Loaded with Ursolic Acid for Breast Cancer TherapY
10.1021/acsanm.3c06161 · 2024 · External reference
Chitosan-coated poly (lactic-co-glycolide) nanoparticles for dual delivery of doxorubicin and naringin against MCF-7 cells
10.1016/j.jddst.2021.103036 · 2022 · External reference
Principles of nanoparticle design for overcoming biological barriers to drug delivery
10.1038/nbt.3330 · 2015 · External reference
Study on the formation mechanism and effective manipulation of polymorphs and solvates in Osimertinib-Caffeic acid multi-component crystal with distinct properties
10.1016/j.ijpharm.2024.125145 · 2025 · External reference
Afatinib-loaded inhalable PLGA nanoparticles for localized therapy of non-small cell lung cancer (NSCLC)-development and in-vitro efficacy
10.1007/s13346-020-00802-8 · 2021 · External reference
10.3390/pharmaceutics11120685
10.3390/pharmaceutics11120685 · External reference
10.3390/pharmaceutics13101686
10.3390/pharmaceutics13101686 · External reference
10.3390/polym17223055
10.3390/polym17223055 · External reference
Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer
10.1016/j.msec.2019.01.066 · 2019 · External reference
10.3389/fchem.2023.1044953
10.3389/fchem.2023.1044953 · External reference
Changes in electric properties of human breast cancer cells
10.1007/s00232-012-9516-5 · 2013 · External reference
Glycosphingolipid composition of MDA-MB-231 and MCF-7 human breast cancer cell lines
10.1023/a:1005986606010 · 1998 · External reference
A comprehensive review of cancer drug nanoparticles synthesis, processing technology and its effect in drug delivery
10.1016/j.bmt.2025.100085 · 2025 · External reference
Cellular Uptake of Nanoparticles: Journey Inside the Cell
10.1039/c6cs00636a · 2017 · External reference
Uptake of Upconverting Nanoparticles by Breast Cancer Cells: Surface Coating versus the Protein Corona
10.1021/acsami.1c10618 · 2021 · External reference
Triple-negative breast cancer central nervous system metastases from the laboratory to the clinic
10.1097/ppo.0000000000000503 · 2021 · External reference
10.3390/pharmaceutics18010134
10.3390/pharmaceutics18010134 · External reference
10.1371/journal.pone.0234012
10.1371/journal.pone.0234012 · External reference
The underlying difference of metastatic and non-metastatic breast cancer cells in configuring type I collagen fibres to promote migration by cell mechanics
10.1016/j.mbm.2025.100113 · 2025 · External reference
Disturbing cytoskeleton by engineered nanomaterials for enhanced cancer therapeutics
2023 · External reference
Breaking biological barriers: Engineering polymeric nanoparticles for cancer therapy
10.1016/j.nantod.2024.102552 · 2025 · External reference
Adjuvant Osimertinib: A New Standard of Care
10.1002/onco.13634 · ExternalCitation · doi-reference
Changes in electric properties of human breast cancer cells
10.1007/s00232-012-9516-5 · ExternalCitation · doi-reference
Novel Silibinin Loaded Chitosan-Coated PLGA/PCL Nanoparticles Based Inhalation Formulations with Improved Cytotoxicity and Bioavailability for Lung Cancer
10.1007/s12668-020-00797-z · ExternalCitation · doi-reference
Afatinib-loaded inhalable PLGA nanoparticles for localized therapy of non-small cell lung cancer (NSCLC)-development and in-vitro efficacy
10.1007/s13346-020-00802-8 · ExternalCitation · doi-reference
Pulmonary delivery of osimertinib liposomes for non-small cell lung cancer treatment: Formulation development and in vitro evaluation
10.1007/s13346-021-01088-0 · ExternalCitation · doi-reference
Targeting EGFR in Lung Cancer: Current Standards and Developments
10.1007/s40265-018-0916-4 · ExternalCitation · doi-reference
A comprehensive review of cancer drug nanoparticles synthesis, processing technology and its effect in drug delivery
10.1016/j.bmt.2025.100085 · ExternalCitation · doi-reference
Chitooligosaccharides-modified PLGA nanoparticles enhance the antitumor efficacy of AZD9291 (Osimertinib) by promoting apoptosis
10.1016/j.ijbiomac.2020.06.154 · ExternalCitation · doi-reference
Study on the formation mechanism and effective manipulation of polymorphs and solvates in Osimertinib-Caffeic acid multi-component crystal with distinct properties
10.1016/j.ijpharm.2024.125145 · ExternalCitation · doi-reference
Chitosan-coated poly (lactic-co-glycolide) nanoparticles for dual delivery of doxorubicin and naringin against MCF-7 cells
10.1016/j.jddst.2021.103036 · ExternalCitation · doi-reference
Paclitaxel and Lapatinib dual loaded chitosan-coated PLGA nanoparticles enhance cytotoxicity by circumventing MDR1-mediated trastuzumab resistance in HER2 positive breast cancers: In-vitro and in-vivo studies
10.1016/j.jddst.2022.103445 · ExternalCitation · doi-reference
The underlying difference of metastatic and non-metastatic breast cancer cells in configuring type I collagen fibres to promote migration by cell mechanics
10.1016/j.mbm.2025.100113 · ExternalCitation · doi-reference
Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer
10.1016/j.msec.2019.01.066 · ExternalCitation · doi-reference
Breaking biological barriers: Engineering polymeric nanoparticles for cancer therapy
10.1016/j.nantod.2024.102552 · ExternalCitation · doi-reference
Uptake of Upconverting Nanoparticles by Breast Cancer Cells: Surface Coating versus the Protein Corona
10.1021/acsami.1c10618 · ExternalCitation · doi-reference
Chitosan-Coated Poly(lactic-co-glycolic acid) Nanoparticles Loaded with Ursolic Acid for Breast Cancer TherapY
10.1021/acsanm.3c06161 · ExternalCitation · doi-reference
An Osimertinib-Perfluorocarbon Nanoemulsion with Excellent Targeted Therapeutic Efficacy in Non-small Cell Lung Cancer: Achieving Intratracheal and Intravenous Administration
10.1021/acsnano.2c04159 · ExternalCitation · doi-reference
Glycosphingolipid composition of MDA-MB-231 and MCF-7 human breast cancer cell lines
10.1023/a:1005986606010 · ExternalCitation · doi-reference
Principles of nanoparticle design for overcoming biological barriers to drug delivery
10.1038/nbt.3330 · ExternalCitation · doi-reference
Cellular Uptake of Nanoparticles: Journey Inside the Cell
10.1039/c6cs00636a · ExternalCitation · doi-reference
Triple-negative breast cancer central nervous system metastases from the laboratory to the clinic
10.1097/ppo.0000000000000503 · ExternalCitation · doi-reference
Triple-negative breast cancer molecular subtyping and treatment progress
10.1186/s13058-020-01296-5 · ExternalCitation · doi-reference
10.1371/journal.pone.0234012
10.1371/journal.pone.0234012 · ExternalCitation · doi-reference
FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation
10.1634/theoncologist.2017-0425 · ExternalCitation · doi-reference
Chitosan-Coated-PLGA Nanoparticles Enhance the Antitumor and Antimigration Activity of Stattic—A STAT3 Dimerization Blocker
10.2147/ijn.s337093 · ExternalCitation · doi-reference
Single emulsion-solvent evaporation technique and modifications for the preparation of pharmaceutical polymeric nanoparticles
10.2174/187221112802652633 · ExternalCitation · doi-reference
10.3389/fchem.2023.1044953
10.3389/fchem.2023.1044953 · ExternalCitation · doi-reference
10.3390/cancers17040668
10.3390/cancers17040668 · ExternalCitation · doi-reference
10.3390/coatings11010006
10.3390/coatings11010006 · ExternalCitation · doi-reference
EGFR Mutations in Surgically Resected Fresh Specimens from 697 Consecutive Chinese Patients with Non-Small Cell Lung Cancer and Their Relationships with Clinical Features
10.3390/ijms141224549 · ExternalCitation · doi-reference
10.3390/ph14060589
10.3390/ph14060589 · ExternalCitation · doi-reference
10.3390/ph15050542
10.3390/ph15050542 · ExternalCitation · doi-reference
10.3390/pharmaceutics11120685
10.3390/pharmaceutics11120685 · ExternalCitation · doi-reference
10.3390/pharmaceutics13101686
10.3390/pharmaceutics13101686 · ExternalCitation · doi-reference
10.3390/pharmaceutics18010134
10.3390/pharmaceutics18010134 · ExternalCitation · doi-reference
10.3390/polym17223055
10.3390/polym17223055 · ExternalCitation · doi-reference
10.3390/pr10071329
10.3390/pr10071329 · ExternalCitation · doi-reference
